Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
Identifieur interne : 008834 ( Main/Exploration ); précédent : 008833; suivant : 008835Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
Auteurs : B V Babu [Inde] ; S K KarSource :
- Tropical medicine & international health : TM & IH [ 1360-2276 ] ; 2004.
Descripteurs français
- KwdFr :
- Adolescent, Albendazole (effets indésirables), Albendazole (usage thérapeutique), Antiprotozoaires (effets indésirables), Antiprotozoaires (usage thérapeutique), Association de médicaments, Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Femelle, Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (épidémiologie), Humains, Inde (épidémiologie), Maladies endémiques (), Mâle, Observance thérapeutique, Personnel de santé (enseignement et éducation), Évaluation de programme ().
- MESH :
- effets indésirables : Albendazole, Antiprotozoaires, Diéthylcarbamazine, Filaricides.
- enseignement et éducation : Personnel de santé.
- usage thérapeutique : Albendazole, Antiprotozoaires, Diéthylcarbamazine, Filaricides.
- épidémiologie : Filariose lymphatique, Inde.
- Adolescent, Association de médicaments, Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique, Humains, Maladies endémiques, Mâle, Observance thérapeutique, Évaluation de programme.
- Wicri :
- geographic : Inde.
English descriptors
- KwdEn :
- Adolescent, Albendazole (adverse effects), Albendazole (therapeutic use), Antiprotozoal Agents (adverse effects), Antiprotozoal Agents (therapeutic use), Child, Child, Preschool, Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Endemic Diseases (prevention & control), Female, Filaricides (adverse effects), Filaricides (therapeutic use), Health Personnel (education), Humans, India (epidemiology), Male, Patient Compliance, Program Evaluation (methods).
- MESH :
- chemical , adverse effects : Albendazole, Antiprotozoal Agents, Diethylcarbamazine, Filaricides.
- chemical , therapeutic use : Albendazole, Antiprotozoal Agents, Diethylcarbamazine, Filaricides.
- geographic , epidemiology : India.
- education : Health Personnel.
- epidemiology : Elephantiasis, Filarial.
- methods : Program Evaluation.
- prevention & control : Elephantiasis, Filarial, Endemic Diseases.
- Adolescent, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Male, Patient Compliance.
Abstract
This paper reports the coverage, compliance and other operational issues of mass drug administration (MDA) of diethylcarbamazine and albendazole under a programme to eliminate lymphatic filariasis (LF) in Orissa state of India. Both quantitative and qualitative methods were used to collect data from 90 villages and nine urban areas of four districts of Orissa, India. In Orissa, 67% of people older than 2 years had received the drugs during MDA and 42% had consumed them. About 25% of people had not taken the tablets although they received them. Urban areas recorded lower rates than rural areas. The paper discusses some policy/health system-, community- and drug-related issues that influenced coverage and compliance of MDA. It is essential to improve compliance in future rounds of MDA to achieve targets of control and eventual elimination of LF in a reasonable time frame.
DOI: 10.1111/j.1365-3156.2004.01247.x
PubMed: 15189460
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003F84
- to stream PubMed, to step Curation: 003F84
- to stream PubMed, to step Checkpoint: 003F84
- to stream Ncbi, to step Merge: 001A21
- to stream Ncbi, to step Curation: 001A21
- to stream Ncbi, to step Checkpoint: 001A21
- to stream Main, to step Merge: 008A94
- to stream Main, to step Curation: 008834
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.</title><author><name sortKey="Babu, B V" sort="Babu, B V" uniqKey="Babu B" first="B V" last="Babu">B V Babu</name><affiliation wicri:level="1"><nlm:affiliation>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, Orissa, India. babubv@satyam.net.in</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, Orissa</wicri:regionArea><wicri:noRegion>Orissa</wicri:noRegion></affiliation></author><author><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15189460</idno><idno type="pmid">15189460</idno><idno type="doi">10.1111/j.1365-3156.2004.01247.x</idno><idno type="wicri:Area/PubMed/Corpus">003F84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003F84</idno><idno type="wicri:Area/PubMed/Curation">003F84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003F84</idno><idno type="wicri:Area/PubMed/Checkpoint">003F84</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003F84</idno><idno type="wicri:Area/Ncbi/Merge">001A21</idno><idno type="wicri:Area/Ncbi/Curation">001A21</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A21</idno><idno type="wicri:doubleKey">1360-2276:2004:Babu B:coverage:compliance:and</idno><idno type="wicri:Area/Main/Merge">008A94</idno><idno type="wicri:Area/Main/Curation">008834</idno><idno type="wicri:Area/Main/Exploration">008834</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.</title><author><name sortKey="Babu, B V" sort="Babu, B V" uniqKey="Babu B" first="B V" last="Babu">B V Babu</name><affiliation wicri:level="1"><nlm:affiliation>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, Orissa, India. babubv@satyam.net.in</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, Orissa</wicri:regionArea><wicri:noRegion>Orissa</wicri:noRegion></affiliation></author><author><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name></author></analytic><series><title level="j">Tropical medicine & international health : TM & IH</title><idno type="ISSN">1360-2276</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Albendazole (adverse effects)</term><term>Albendazole (therapeutic use)</term><term>Antiprotozoal Agents (adverse effects)</term><term>Antiprotozoal Agents (therapeutic use)</term><term>Child</term><term>Child, Preschool</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Endemic Diseases (prevention & control)</term><term>Female</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Health Personnel (education)</term><term>Humans</term><term>India (epidemiology)</term><term>Male</term><term>Patient Compliance</term><term>Program Evaluation (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Albendazole (effets indésirables)</term><term>Albendazole (usage thérapeutique)</term><term>Antiprotozoaires (effets indésirables)</term><term>Antiprotozoaires (usage thérapeutique)</term><term>Association de médicaments</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Inde (épidémiologie)</term><term>Maladies endémiques ()</term><term>Mâle</term><term>Observance thérapeutique</term><term>Personnel de santé (enseignement et éducation)</term><term>Évaluation de programme ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Antiprotozoal Agents</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Antiprotozoal Agents</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>India</term></keywords><keywords scheme="MESH" qualifier="education" xml:lang="en"><term>Health Personnel</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Antiprotozoaires</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="enseignement et éducation" xml:lang="fr"><term>Personnel de santé</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Program Evaluation</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Endemic Diseases</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antiprotozoaires</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Inde</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Patient Compliance</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Association de médicaments</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Maladies endémiques</term><term>Mâle</term><term>Observance thérapeutique</term><term>Évaluation de programme</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This paper reports the coverage, compliance and other operational issues of mass drug administration (MDA) of diethylcarbamazine and albendazole under a programme to eliminate lymphatic filariasis (LF) in Orissa state of India. Both quantitative and qualitative methods were used to collect data from 90 villages and nine urban areas of four districts of Orissa, India. In Orissa, 67% of people older than 2 years had received the drugs during MDA and 42% had consumed them. About 25% of people had not taken the tablets although they received them. Urban areas recorded lower rates than rural areas. The paper discusses some policy/health system-, community- and drug-related issues that influenced coverage and compliance of MDA. It is essential to improve compliance in future rounds of MDA to achieve targets of control and eventual elimination of LF in a reasonable time frame.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><noCountry><name sortKey="Kar, S K" sort="Kar, S K" uniqKey="Kar S" first="S K" last="Kar">S K Kar</name></noCountry><country name="Inde"><noRegion><name sortKey="Babu, B V" sort="Babu, B V" uniqKey="Babu B" first="B V" last="Babu">B V Babu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008834 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008834 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15189460
|texte= Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15189460" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |